Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
Yonsei Medical Journal
;
: 800-806, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-81892
ABSTRACT
PURPOSE:
To investigate the efficacy and safety of naftopidil for benign prostatic hyperplasia (BPH) patients, mainly focusing on changes in blood pressure (BP). MATERIALS ANDMETHODS:
Of a total of 118 patients, 90 normotensive (NT) and 28 hypertensive (HT) patients were randomly assigned to be treated with naftopidil 50 mg or 75 mg for 12 weeks, once-daily. Safety and efficacy were assessed by analyzing changes from baseline in systolic/diastolic BP and total International Prostate Symptom Score (IPSS) at 4 and 12 weeks. Adverse events (AEs), obstructive/irritative subscores, quality of life (QoL) score, maximum urinary flow rate (Qmax), and benefit, satisfaction with treatment, and willingness to continue treatment (BSW) questionnaire were also analyzed.RESULTS:
Naftopidil treatment decreased mean systolic BP by 18.7 mm Hg for the HT 50 mg group (p86% of all patients agreed to continue their current medications.CONCLUSION:
Our results suggest that naftopidil treatment in BPH patients with hypertension allows for optimal management of BP within the normal range.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Próstata
/
Hiperplasia Prostática
/
Calidad de Vida
/
Valores de Referencia
/
Presión Sanguínea
/
Estudios Prospectivos
/
Resultado del Tratamiento
/
Hipertensión
Tipo de estudio:
Estudio observacional
Límite:
Humanos
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS